Dream Valley Presents Innovation at SLEEP 2024 to Help Facilitate Deep Sleep
11 juin 2024 09h00 HE
|
Dream Valley
Houston, June 11, 2024 (GLOBE NEWSWIRE) -- Shadow Wang, chief executive officer of Dream Valley, emphasized the importance of deep sleep during his presentation at the SLEEP 2024 event, the 38th...
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
11 juin 2024 08h45 HE
|
FN Media Group LLC
PALM BEACH, Fla., June 11, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - In the last twenty years, the amount of people with multiple sclerosis (MS) in the United States has more than...
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
11 juin 2024 08h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
11 juin 2024 07h59 HE
|
Sixty Degrees Pharmaceuticals
60 Degrees Pharmaceuticals receives FDA orphan drug status for tafenoquine to treat acute babesiosis, offering market exclusivity and tax incentives.
Kronos Advanced Technologies Inc Maintains Leadership As The First Public Company To Embrace Shiba Inu: A Leap Into The Future Of E-Commerce Payments
10 juin 2024 15h01 HE
|
Kronos Advanced Technologies Inc.
Los Angeles, CA , June 10, 2024 (GLOBE NEWSWIRE) -- Kronos Advanced Technologies Inc. (OTC: KNOS), a leading innovator in air purification solutions, is thrilled to announce the acceptance of Shiba...
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
06 juin 2024 09h00 HE
|
Tiziana Life Sciences Ltd.
Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months.FDA...
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
03 juin 2024 08h30 HE
|
Nexalin Technology, Inc.
HOUSTON, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announces that the U.S. Food and Drug Administration (FDA) has provided...
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
03 juin 2024 07h05 HE
|
uniQure Inc.
~ Designation based on 24-month interim Phase I/II clinical data for AMT-130 announced in December 2023 ~ ~ AMT-130 is the first therapeutic candidate to receive RMAT Designation for Huntington’s...
New AAMI Guidance on Combination Products and FDA CGMPs
30 mai 2024 08h47 HE
|
AAMI
Arlington, Virginia, May 30, 2024 (GLOBE NEWSWIRE) -- As the breadth and scope of combination products around the world continues to ramp up, are U.S. manufacturers equipped with the best design...
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
28 mai 2024 16h30 HE
|
Axogen, Inc.
ALACHUA, Fla. and TAMPA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,...